A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
Condition: Hypercholesterolemia · Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
About this study
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors. The efficacy and safety of SHR-1918 will be evaluated after 12-weeks and 24-weeks treatment.
This description comes directly from the study's public registry record.
Talk to the study team
Miaomiao Shi · +86-0518-82342973 · miaomiao.shi@hengrui.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Nanjing First Hospital | Nanjing, Jiangsu, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07404553